Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Liver Cirrhoses, Portal Hypertension Rel...
Phase PHASE4
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Transjugular Intrahepatic Portosystemic Shunt (TIPS) — Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.
  • Procedure: Sleeve Gastrectomy — Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.
  • Drug: Anti-Obesity Pharmacotherapy (Class Effect) — Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.
  • Behavioral: Lifestyle Counseling - Diet & Physical-Activity Program — Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.

Primary Outcomes

  • Change in SF-36 Physical Component Summary (PCS) Score From Baseline to 6 Months (At 6 months after treatment initiation (Day 0 = TIPS placement date or start of medical management).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-12-17
Completion: 2034-02-01
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Cleveland Clinic
Collaborators: Ali Aminian, MD
Principal Investigators:
  • Sobia Laique, MD (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Awwab F Hammad, MD
+1 216 444 5022
hammada4@ccf.org
Erlind Allkushi
ALLKUSE2@ccf.org
Awwab F Hammad, MD
+1 216 444 5022
hammada4@ccf.org
Cleveland Clinic Main Campus
Interventions
  • Procedure: Transjugular Intrahepatic Portosystemic Shunt (TIPS) — Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.
  • Procedure: Sleeve Gastrectomy — Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.
  • Drug: Anti-Obesity Pharmacotherapy (Class Effect) — Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.
  • Behavioral: Lifestyle Counseling - Diet & Physical-Activity Program — Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.
Study Locations (1 sites)
Cleveland Clinic Main Campus, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria 1. Candidate for general anesthesia. 2. Age 18-70 years at consent. 3. BMI 35-70 kg/m² at first study visit. 4. Eligible for sleeve gastrectomy per ASMBS/IFSO 2022 guidelines. 5. Insurance coverage for metabolic surgery. 6. Current or prior anti-obesity medication use permitted. 7. Liver cirrhosis confirmed by biopsy or non-invasive assessment. 8. Clinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices / portal-hypertensive gastropathy, or imaging evidence of collaterals/dilated portal vein). 9. Able and willing to provide informed consent and comply with study procedures. 10. Women of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years. Exclusion Criteria 1. Prior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier). 2. Prior complex foregut surgery. 3. History of solid-organ transplant. 4. Severe pulmonary disease (FEV1 \< 50 % predicted). 5. Significant cardiac or atherosclerotic disease with planned re-vascularization within 12 months. 6. ASA class IV or V uncompensated cardiopulmonary disease. 7. Left-ventricular ejection fraction \< 25 % or MI/unstable angina/stroke/heart surgery/coronary stent within 6 months. 8. Hiatal hernia \> 7 cm or LA grade C/D erosive esophagitis. 9. Active Crohn's disease. 10. Severe psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol/substance abuse within 12 months. 11. Pregnant, breastfeeding, planning pregnancy, or not using adequate contraception. 12. Malignancy within the prior 12 months (except non-melanoma skin cancer). 13. Life expectancy \< 2 years in investigator's judgment. 14. Investigational therapy within 3 months. 15. Acute pancreatitis ≤ 90 days. 16. Portal vein thrombosis at screening. 17. Decompensated cirrhosis (moderate/large ascites, hepatic encephalopathy, or listed for liver transplant); small ascites or prior variceal bleed allowed. 18. Total bilirubin \> 3 mg/dL, INR \> 1.7, or platelets \< 50 000/µL (within 1 month). 19. Significant alcohol intake (\> 14 units/week women, \> 21 units/week men) within the prior 12 months. 20. eGFR \< 45 mL/min/1.73 m² or on dialysis (within 1 month). 21. AIDS. 22. Unable to understand study or give consent. 23. Plans to move more than 3 hours from Cleveland within 6 months. 24. Previous randomization in this trial. 25. Any condition that, in the investigator's opinion, places the subject at undue risk.
Conditions Primary Hypertension
Phase Not Applicable
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Children and adolescents with primary hypertension (high blood pressure without an underlying secondary cause) are at increased risk of cardiovascular disease in adulthood. Recent research suggests that not only the heart and blood vessels, but also the bacteria living in the mouth may play a role in blood pressure regulation. Certain oral bacteria can convert nitrate from food into nitrite and then into nitric oxide, a substance that helps blood vessels relax. If this nitrate-nitrite-nitric oxide pathway is impaired, blood pressure may rise. This study aims to investigate the relationship between oral microbiota, salivary nitric oxide reductase activity and blood pressure in children and adolescents with primary hypertension compared with healthy peers. We will recruit participants aged 10-18 years who have a diagnosis of primary hypertension and an age- and sex-matched control group without hypertension. All participants will undergo a non-invasive oral and dental examination and standardized blood pressure measurements. Saliva samples will be collected to measure pH, flow rate, nitrate and nitrite levels, total protein, lysozyme activity and to analyze the composition of oral bacteria using modern DNA-based techniques. Participants and/or their parents will also complete brief questionnaires about diet and general health. No medication or dietary supplement will be given as part of the study, and no additional blood samples will be taken beyond routine clinical care. The main risk is minimal discomfort related to oral examination and saliva collection. There is no guaranteed direct benefit for participants; however, the results may help us better understand how oral bacteria and salivary nitric oxide pathways are linked to high blood pressure in young people. This knowledge may support the development of new non-invasive strategies for early detection and prevention of hypertension in the future.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Other: No active intervention — This is an observational study with no active intervention. No drug, device, behavioral, dietary, surgical, or diagnostic intervention is administered to participants. All study procedures, including oral examination, salivary sampling, pH measurement, biochemical tests, and blood pressure assessment, are non-interventional and part of standard clinical evaluation. The study only aims to observe natural variations in oral microbiota composition, nitrate-reducing activity, and blood pressure without changing participants' medical care.

Primary Outcomes

  • Microbiota Composition (16S rRNA Sequencing) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-15
Completion: 2027-01-15
Eligibility
Age: 10 Years – 18 Years
Sex: ALL
Volunteers: true
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yelda Kasımoğlu
Collaborators: Istanbul University Scientific Research Projects Coordination Unit- Pending
Contact Information
Study Contact:
Yelda Kasimoglu Assoc. Prof.
+90 533 623 39 78
yelda.kasimoglu@iu.edu.tr
Yelda Kasimoglu, Assoc. Prof.
+90 533 623 39 78
yelda.kasimoglu@iu.edu.tr
Istanbul University Faculty of Dentistry
Interventions
  • Other: No active intervention — This is an observational study with no active intervention. No drug, device, behavioral, dietary, surgical, or diagnostic intervention is administered to participants. All study procedures, including oral examination, salivary sampling, pH measurement, biochemical tests, and blood pressure assessment, are non-interventional and part of standard clinical evaluation. The study only aims to observe natural variations in oral microbiota composition, nitrate-reducing activity, and blood pressure without changing participants' medical care.
Study Locations (1 sites)
Istanbul University Faculty of Dentistry, Istanbul, Fatih 34093 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Applied to the Istanbul University Faculty of Medicine, Department of Pediatric Nephrology, * Between the ages of 10 and 18, * Diagnosed with primary hypertension, * Clinically excluded from secondary hypertension or heart failure, * No systemic or chronic disease other than hypertension, * No periodontal disease, dental infection, or oral mucosal disease, * Not taking regular antihypertensive or other medications for a chronic disease, * Not having received antibiotic treatment in the last 3 months, * Patients who have not used mouthwash in the last 3 months, * Have no allergies to nitrate-rich foods, * Both male and female patients will be included. Exclusion Criteria: * Younger than 10 years of age or older than 18 years of age * Clinically diagnosed with secondary hypertension or heart failure * Have a systemic disease * Have periodontal disease, dental infection, or oral mucosal disease * Are taking regular antihypertensive medications or other chronic illnesses * Have received antibiotic treatment within the last 3 months * Have used mouthwash within the last 3 months * Are allergic to nitrate-rich foods will not be included in the study.
Conditions Cataract, Glaucoma
Phase Not Applicable
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

You were selected to participate in this observational study because you suffer from glaucoma and cataracts. For the cataract you will have cataract surgery. This study will not affect your treatment, it will only collect data on what is performed before, during and after the procedure. The aim of this data collection is to demonstrate the safety of a new generation of cataract surgical devices in patients who also suffer from glaucoma. They are glaucoma patients who have an increased sensitivity to eye pressure increases both during and after surgery. The new surgical device makes it possible to safely perform cataract surgery under low pressures. This could, at least theoretically, provide an advantage for patients who also suffer from glaucoma.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Complication rate during cataract surgery (Month 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-12
Completion: 2025-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Visionair Oogzorg
Principal Investigators:
  • Koen Willekens (PRINCIPAL_INVESTIGATOR) - Visionair Oogzorg
Contact Information
Study Contact:
Koen Willekens, Prof
003214808311
kw@visionairoogzorg.be
Sien Boons
003216715634
sb@visionairoogzorg.be
Sien Boons
+3214808311
sb@visionairoogzorg.be
Visionair Oogzorg
Interventions
N/A
Study Locations (1 sites)
Visionair Oogzorg, Geel, 2400 Belgium
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with glaucoma that are diagnosed with age-related cataract Exclusion Criteria: * Unwilling to sign informed consent * Functionally monophtalmic patient * Endothelial dystrophy * Active uveitis * Known corticosteroid responder * Presence of uncontrolled systemic disease
Conditions Hypercholesterolaemia
Phase PHASE2
Enrollment 120
Locations 29 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: QCZ484 — QCZ484 once on Day 1
  • Drug: Inclisiran — Inclisiran once on Day 1
  • Drug: QCZ484 placebo — QCZ484 placebo once on Day 1
  • Drug: Inclisiran placebo — Inclisiran placebo once on Day 1

Primary Outcomes

  • Percent change from baseline of PCSK9 levels (Baseline and Month 3)
  • Percent change from baseline of AGT levels (Baseline and Month 3)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-29
Completion: 2028-02-03
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novartis Pharmaceuticals
Principal Investigators:
  • Novartis Pharmaceuticals (STUDY_DIRECTOR) - Novartis Pharmaceuticals
Contact Information
Study Contact:
Novartis Pharmaceuticals
1-888-669-6682
novartis.email@novartis.com
Novartis Pharmaceuticals
Christine S Fuller
glresearch5@gmail.com
G and L Research LLC
Interventions
  • Drug: QCZ484 — QCZ484 once on Day 1
  • Drug: Inclisiran — Inclisiran once on Day 1
  • Drug: QCZ484 placebo — QCZ484 placebo once on Day 1
  • Drug: Inclisiran placebo — Inclisiran placebo once on Day 1
Study Locations (29 sites)
G and L Research LLC, Foley, Alabama 36535 United States
The Center for Clinical Trials, Saraland, Alabama 36571 United States
Clinical Trials Research, Lincoln, California 95648 United States
Downtown L A Research Center Inc, Los Angeles, California 90017 United States
Valley Clinical Trials, Northridge, California 91325 United States
Flourish Medical Clinical Trials, Boca Raton, Florida 33434 United States
Clinical Research of Brandon LLC, Brandon, Florida 33511 United States
ALL Medical Research LLC, Cooper City, Florida 33024 United States
AMR Miami, Coral Gables, Florida 33134 United States
Universal Axon Clinical Research, Doral, Florida 33166 United States
Eligibility Criteria
Inclusion Criteria: * Males or females aged 18 to 75 years. * Diagnosis of primary hypertension. * Treatment with either no, or up to 2 antihypertensive medications at a stable dose for at least 4 weeks preceding screening. * Systolic blood pressure ≥140 and \<165 mmHg based on the mean of 3 sitting measurements based on office blood pressure monitoring. * Diagnosis of hypercholesterolemia including heterozygous familial hypercholesterolemia unable to reach LDL-C goals with a stable dose of statin treatment for at least 4 weeks prior to screening as per Investigator judgement, guidelines and local practice (if tolerated and not contraindicated) with or without bempedoic acid and with or without ezetimibe prescribed according to local guidance, at a stable dose for at least 4 weeks preceding Screening Visit 1. The following parameters must be confirmed at Screening Visit 2: * Fasting serum LDL-C ≥70 mg/dL and \<190 mg/dL using Friedewald equation. * Fasting triglyceride \<400 mg/dL. Exclusion Criteria: * Symptomatic orthostatic hypotension. * Treatment with certain medications and/or unable to comply with prohibited medications requirements. Other protocol inclusion/exclusion criteria may apply
Conditions Atherosclerosis Cardiovascular Disease
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Background: Hypertension (HT) is the most common condition worldwide, predisposing to atherosclerotic disease. However, most HT patients have suboptimal BP control despite anti-HT medications. Isometric resistance exercise (IRE) (e.g. wall squat) may improve BP control, characterized by sustained muscle contraction with minimal change in muscle length and joint angle. Most randomized trials of IRE are short duration and their long-term effects on BP and atherosclerotic complications, particularly in the Chinese, remain unknown. Study objectives: (i) To evaluate the impact of IRE on atherogenesis surrogates (brachial flow-mediated dilation, FMD and carotid intima-media thickness IMT). (ii) To evaluate the impact of IRE on mechanisms of atherogenesis improvement, inflammatory parameters, arterial wall stiffness and biochemical profiles. Setting: Randomized samples of 200 HT patients, aged \>18years with systolic BP 135-160mHg while on no or stable anti-HT medications. Design: Randomized controlled IRE trial - stratified randomization with randomization block size of 4. 1. 100 patients for wall squat exercise of 14 mins each session (2 mins IRE x 4 sets, 2 mins rest in between), 3 sessions per week, for 1 year, plus advice on healthy diet and lifestyle. 2. 100 control patients (usual care) with advice on diet and healthy lifestyles and simple stretching exercise programme for 1 year. Main outcome measures: 1. Brachial FMD and carotid IMT at baseline, 24 weeks and 1 year. (primary outcome) 2. Carotid-femoral pulse wave velocity (cf-PWV) at baseline and 24 weeks. (secondary outcome) 3. Important atherosclerosis risk factor parameters at baseline, 24 weeks and 1 year - including fasting serum glucose, lipid profiles, HgbA1-C, creatinine, hs-CRP, CBP, fibrinogen, and interleukin 6 (IL-6). (secondary outcome) 4. Safety profiles (if any) including CVS event and hospitalization at 1 year. Expected results: A group absolute difference in FMD of 1%, and in carotid IMT of 0.06mm between IRE intervention and control groups. Implications: IRE as suggested will be beneficial to management of HT for atherosclerosis preventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Squatting Exercise — 14 minutes per session (2 mins x 4 sets, 2 mins rest in between, 3 session per week)
  • Other: Stretching (Yoga) Exercise — 2 mins x 4 sets, 2 mins rest in between, 3 sessions per week

Primary Outcomes

  • The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension (Baseline, 24 weeks and 1 year)
  • The Impact of Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension (Baseline, 24 weeks and 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-16
Completion: 2027-12-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Kam Sang Woo (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
KS Woo, MBBS, MD, FACC
+852 26474966
kamsangwoo@cuhk.edu.hk
Kam Sang Woo, MBBS, MD, FACC
+852 26474966
kamsangwoo@cuhk.edu.hk
The Chinese University of Hong Kong, Department of Medicine & Therapeutics
Daphne Chu
daphne.chu@cuhk.edu.hk
The Chinese University of Hong Kong, Department of Medicine & Therapeutics
Interventions
  • Other: Squatting Exercise — 14 minutes per session (2 mins x 4 sets, 2 mins rest in between, 3 session per week)
  • Other: Stretching (Yoga) Exercise — 2 mins x 4 sets, 2 mins rest in between, 3 sessions per week
Study Locations (1 sites)
The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. asymptomatic clinically stable adults 2. aged \>18 years 3. Both genders 4. Suboptimal BP (on stable medication) with SBP 135-160mmHG on ambulatory BP monitoring (AMBP) 5. Agreeable to no drug changes in coming 1 year 24 weeks 6. Agreeable to provide informed written consent form 7. Agreeable to have AMBP and ultrasonic (FMD \& IMT) scan third (baseline, 24 weeks and preferably 1 year) Exclusion Criteria: 1. relative contraindications to AMBP (e.g. atrial fibrillation) 2. severe osteoarthritis of knee 3. known secondary HT 4. pregnancy/breastfeeding 5. active malignancy 6. Serious coronary profiles, (unstable angina), renal or hepatic derangement 7. Need to change medications for control BP at 24 weeks ( SBP\>160 mmHg)
Conditions Preeclampsia
Phase Not Applicable
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Although extensively studied, the cause of preeclampsia remains uncertain other than it is thought that the placenta plays a critical role in the development of preeclampsia. Recent data revealed that exosomes released from the placenta could cause preeclampsia by transporting specific cargo responsible for the pathophysiological changes associated with the systemic disease. By isolating these exosomes from maternal blood and placental tissue in patients diagnosed with preeclampsia and studying their biochemical, cellular and molecular mechanism in an animal model, the investigators hope to elucidate the critical role that exosomal cargo plays in the development of preeclampsia and cardiovascular remodeling. This will be accomplished by obtaining patient samples from volunteers delivering at the Women and Infants Center and taking the samples to the lab for quantification, characterization, and identification of key functional roles through in/ex vivo, in vitro, and profiling studies. The investigators believe this work will be valuable as hope exists to define the functional role exosomes play in the development of preeclampsia that leads to cardiovascular remodeling. Data from this study will shed more light on the functional role of exosomal cargo in normal and pathological pregnancies and point towards novel therapeutic intervention strategies for preeclampsia associated with cardiovascular disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Sample collection — Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.

Primary Outcomes

  • Exosome cargo levels (Through study completion, average of four hours of involvement time total, after informed consent discussion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-12-02
Completion: 2031-12-15
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Principal Investigators:
  • Teshi Kaushik, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Shanna H Graves
205-975-2845
shannagraves@uabmc.edu
Ayesha Bryant, MD, MSPH
205-934-4696
Asbryant@uabmc.edu
Kera N Marshall, BS
205-934-4042
Keramarshall@uabmc.edu
University of Alabama at Birmingham
Interventions
  • Other: Sample collection — Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
Study Locations (1 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35233 United States
Eligibility Criteria
Inclusion 1. Preeclampsia patients: Age ≥ 18 years; Diagnosis of preeclampsia with severe features: 1. BP ≥160/110 after 20 weeks gestation AND ≥300 mg/day proteinuria or protein/creatinine ratio of 0.3 mg/dL; OR 2. BP ≥160/110 after 20 weeks gestation with any of the following co-conditions: platelet count less than 100,000 X 109/L, AST/ALT enzymes elevated to twice the upper limit of normal, serum creatinine ≥1.1 mg/dL or a doubling of the creatinine from baseline, pulmonary edema, new-onset headache, and/or visual disturbances. 2. Control patients: Age ≥ 18 years; no diagnosis of preeclampsia or any pregnancy-induced hypertension disorder. 3. Pre-clampsia patients will be defined as =140 mmHg systolic or =90mmHg diastolic BP with at least at least 2 occasions 4 hours apart after 20 weeks of gestation in previously normotensive women with at least one of the following symptoms: =300 mg/day proteinuria, protein/creatinine ratio of 0.3 mg/dL, platelet count \< 100,000 X 109/L, elevated liver enzymes, serum creatinine =1.1 mg/dL, pulmonary edema, or new-onset headache or visual disturbances. 1. \>22w 0d gestational age -33w 6d GA (n=16) 2. \>= 34 wGA (n=16) 4. Pre-eclampsia with severe features will be defined as blood pressure =160 mmHg systolic or =110 mmHg diastolic BP at least 2 occasions 4 hours apart after 20 weeks of gestation with any of the additional diagnostic criteria listed above. 1. \>22w 0d gestational age -33w 6d GA (n=16) 2. \>= 34 wGA (n=16) 5. Healthy gestational age matched controls: 1. \>22w 0d gestational age -33w 6d GA (n=32) 2. \>= 34 wGA (n=32) Exclusion criteria: 1. Preeclampsia patients: Age \< 18 years; Any other diagnosis of pregnancy-induced hypertension that isn't preeclampsia with severe features (i.e. gestational hypertension or preeclampsia without severe features). 2. Control Patients: Age \< 18 years; Any diagnosis of pregnancy-induced hypertension.
Conditions Pulmonary Artery Hypertension, Right Ven...
Phase NA
Enrollment 16
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload. Pharmacologic trials have shown that aggressive upfront treatment reversing pulmonary vascular remodeling successfully increases RV function and improves survival. To date, however, there are no proven treatments that target RV contractile function. Echocardiographic studies of RV dysfunction in the setting of pressure overload have demonstrated intra and interventricular dyssynchrony even in the absence of overt right bundle branch block (RBBB). Electrophysiologic studies of patients with chronic thromboembolic disease (CTEPH) at the time of pulmonary endarterectomy have shown prolongation of action potential and slowed conduction in the right ventricle which has correlated with echocardiographic measures of dyssynchrony. Cardiac MRI measures of RV strain in patients with PAH demonstrated simultaneous initiation of RV and left ventricular (LV) contraction, but delayed peak RV strain suggesting that interventricular dyssynchrony is a mechanical rather than electrical phenomenon. Prior studies of RV dysfunction in an animal model, computer model, congenital heart disease, and CTEPH have suggested acute hemodynamic benefits of RV pacing. However, RV pacing has not been studied in patients with PAH. Furthermore, it remains unclear if pacing particular regions of the RV can achieve a hemodynamic benefit and what cost this hemodynamic improvement may incur with regards to myocardial energetics and wall stress. Therefore, the investigators propose to examine RV electrical activation in PAH, map the area of latest activation, and then evaluate the hemodynamic and energetic effects of RV pacing in these patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Temporary right ventricular pacing — As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.

Primary Outcomes

  • Change in contractility (Ees) (During procedure. The measurement will be taken pre-RV pacing, with RV pacing, and 5 minutes after RV pacing. All catheters will then be removed and the study will be completed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-01-01
Completion: 2027-01-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Liviu Klein, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
  • Benjamin W Kelemen, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Benjamin Kelemen, MD
415-476-2143
Benjamin.Kelemen@ucsf.edu
Liviu Klein, MD MS
415-476-2143
Liviu.Klein@ucsf.edu
Benjamin Kelemen, MD
415-476-2143
benjamin.kelemen@ucsf.edu
University of California San Francisco
Interventions
  • Procedure: Temporary right ventricular pacing — As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Study Locations (1 sites)
University of California San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Patients referred for a clinically indicated right heart catheterization to either diagnose pulmonary arterial hypertension prior to initiating therapies or monitor response to ongoing therapies in patients with diagnosed pulmonary arterial hypertension. * Patients with pulmonary arterial hypertension with or without significant right ventricular dysfunction as assessed by baseline echocardiography and standard of care right heart catheterization * Functional class 2 or 3 symptoms * Are able to undergo cardiac MRI, endocardial mapping, and pressure volume measurements * English speaking * All patients will be required to have evidence of right ventricular hypertrophy or conduction delay (QRS \> 130ms) on surface ECG Exclusion Criteria: * Preexisting left bundle branch block, current atrial fibrillation, or pacemaker/ defibrillators * Functional class 4 symptoms * Patients treated with parenteral or subcutaneous therapies for pulmonary hypertension * Contraindication to right heart catheterization including significant thrombocytopenia (platelets \< 50,000), coagulopathy (INR \> 1.8), or pregnancy as determined by routine screening laboratory work * Mean pulmonary artery pressure less than 25 mmHg as determined by the right heart catheterization on the day of the study procedure * Pulmonary capillary wedge pressure greater than or equal to 15 mmHg as determined by the right heart catheterization on the day of the study procedure * Severe tricuspid regurgitation as determined by baseline transthoracic echocardiogram. * Left ventricular dysfunction (EF \< 50%) as determined by baseline transthoracic echocardiogram. * Inability to complete cardiac MRI or transthoracic echocardiography * Patients with confounding systemic disease specifically portopulmonary hypertension and scleroderma associated pulmonary hypertension * Patients otherwise deemed not appropriate for the study as determined by the study investigators
Conditions Pregnancy, Pregnancy - Prenatal Testing,...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension during pregnancy is a major public health concern, increasing the risk of cardiovascular complications for both the mother and the fetus. Women with chronic hypertension are at higher risk of adverse outcomes, and elevated blood pressure during pregnancy has also been associated with long-term cardiovascular and cognitive impairments.Regular physical activity is recognized as an effective non-pharmacological strategy to reduce blood pressure. Among different exercise modalities, isometric exercise has shown promising effects in lowering blood pressure in the general population, with minimal cardiovascular strain. However, its effects and safety in pregnant women, particularly those with hypertension, remain poorly understood.In addition to cardiovascular alterations, hypertension during pregnancy may also impact cognitive function, potentially through changes in cerebral perfusion and vascular function. Despite these associations, the combined cardiovascular and cognitive responses to exercise in this population have not been fully explored.This study aims to investigate the effects of isometric handgrip exercise on cardiovascular and cognitive responses in pregnant women with and without chronic hypertension, in order to better understand its potential as a safe and effective non-pharmacological intervention during pregnancy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Isometric Handgrip Exercise — Isometric handgrip exercise performed at 30% of maximal voluntary contraction, consisting of four 2-minute contractions with one-minute rest intervals between efforts. The exercise is performed using a handgrip dynamometer.
  • Behavioral: Control Rest — Seated rest condition without exercise, used as a control comparison to the isometric handgrip intervention.

Primary Outcomes

  • Systolic and diastolic blood pressure (ambulatory blood pressure measurement) (After sessions (24 hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-06
Completion: 2027-09-30
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Poitiers
Collaborators: Poitiers University Hospital, Laboratory MOVE, Faculty of Sport Sciences, University of Poitiers, France
Contact Information
Study Contact:
Carina ENEA
+33 549 454 495
carina.enea@univ-poitiers.fr
Mélanie Gréau Marias
+33 675 329 599
melanie.greau.marias@univ-poitiers.fr
Mélanie Gréau Marias
+33 675 329 599
melanie.greau.marias@univ-poitiers.fr
Faculty of Sport Science - MOVE Laboratory - UR 20296
Interventions
  • Behavioral: Isometric Handgrip Exercise — Isometric handgrip exercise performed at 30% of maximal voluntary contraction, consisting of four 2-minute contractions with one-minute rest intervals between efforts. The exercise is performed using a handgrip dynamometer.
  • Behavioral: Control Rest — Seated rest condition without exercise, used as a control comparison to the isometric handgrip intervention.
Study Locations (1 sites)
Faculty of Sport Science - MOVE Laboratory - UR 20296, Poitiers, 86000 France
Eligibility Criteria
Inclusion Criteria: * Pregnant women covered by the French National Health Insurance system * Pregnant women who do not object to participation in the study * Women belonging to one of the following two groups: * Women with chronic hypertension present before pregnancy (diagnosed within the past 5 years), defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, without antihypertensive treatment * Normotensive pregnant women, defined as systolic blood pressure (SBP) \< 140 mmHg and diastolic blood pressure (DBP) \< 90 mmHg before pregnancy Exclusion Criteria: * Current treatment for chronic or gestational hypertension * Known cardiovascular disease other than chronic hypertension * Age under 18 years * Persons deprived of liberty * Inability to speak or adequately understand French * Persons hospitalized without consent who are not subject to legal protection measures, and persons admitted to a health or social institution for purposes other than research * Persons currently excluded from participation in another research study * Persons under judicial protection or guardianship Type 1 or type 2 diabetes * Severe or extreme obesity (BMI ≥ 40 kg/m²) * Thyroid disease * Heavy smoking
Conditions BRCA-Mutated Breast Carcinoma, HER2-nega...
Phase PHASE2
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-1167 — a highly selective PARP1 inhibitor
  • Drug: Famitinib — a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
  • Drug: Camrelizumab — a humanised anti-programmed death-1 (anti PD-1) antibody

Primary Outcomes

  • Safety run-in: Incidence rate of dose-limiting toxicities (DLTs) (28±3 days)
  • Safety run-in: adverse events (AEs) (28±3 days)
  • Safety run-in: Serious adverse events (SAEs) (28±3 days)
  • Phase 2: Total Pathologic complete response (tpCR: ypT0/Tis ypN0) rate (Immediately after the surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-30
Completion: 2027-06
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhi-Ming Shao, MD (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Xi-Yu Liu, MD
86-21-64175590-63202
liu-xiyu@163.com
Zhi-Ming Shao, MD
86-21-641755901105
zhimingshao@yahoo.com
Breast cancer institute of Fudan University Cancer Hospital
Interventions
  • Drug: HRS-1167 — a highly selective PARP1 inhibitor
  • Drug: Famitinib — a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
  • Drug: Camrelizumab — a humanised anti-programmed death-1 (anti PD-1) antibody
Study Locations (1 sites)
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age 18 to 70 years old, female. 2. Patients with histologically confirmed unilateral primary invasive breast cancer who meet the criteria of cT0-4, N1-3, M0 or cT≥3, N0, M0 (inflammatory breast cancer not included). 3. Patients with HER-2 negative disease. HER2-negative disease was defined as follows: disease whose HER-2 is 1+ or negative by immunohistochemical (IHC), or fluorescence in situ hybridization (FISH) is negative if IHC is 2+. 4. Patients with pathogenic germline BRCA 1/2 mutation. 5. According to the RECIST 1.1 criteria, there is at least one measurable objective lesion. 6. Eastern Cooperative Oncology Group (ECOG) performance score 0-1. 7. Appropriate haematological, hepatic and renal function (no blood transfusion or hematopoietic stimulating factors within 14 days): 1) Absolute number of neutrophils (ANC) ≥ 1.5 x 10\^9/L; 2) Platelets ≥ 100 x 10\^9/L; 3) Hemoglobin ≥ 90 g/L ; 4) White blood cell (WBC) ≥ 3.0×10\^9/L and ≤15×10\^9/L; 5) Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); 6) AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN; 7) serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance (CrCL) ≥50 mL/min (Cockcroft-Gault equation); 8) Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 ULN with international normalized ratio (INR) ≤1.5 ULN (not receiving anticoagulation); 9) Serum albumin ≥ 2.5g/dL. 8. Left ventricular ejection fraction (LVEF) ≥ 50%. 9. 12-lead ECG: QT interval corrected by Fridericia method (QTcF) \< 470 msec. 10. Urine test: urinary protein \< 2+; If urinary protein ≥ 2+, 24-hour urinary protein quantification must show protein ≤1g. 11. Subject is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. 12. With good compliance with the planned treatment, are able to understand the follow-up procedures of this study and sigh the informed consent form. Exclusion Criteria: Patients with any of the following were not enrolled in the study: 1. Cancer-related history and treatment history: 1) Bilateral breast cancer; 2) Previous history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS); 3) Previous history of invasive or metastatic breast cancer; 4) Any malignant tumor was diagnosed within 3 years before signing the informed consent, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma; 5) Received systemic chemotherapy, systemic targeted therapy and local radiotherapy within 3 years before signing the informed consent; 6) Previously treated with VEGFR small molecule tyrosine kinase inhibitors (such as famitinib, sorafenib, sunitinib, regorafenib, etc.) (except bevacizumab); 7) Prior treatment with PARP inhibitors for any disease; 2. Stage IV breast cancer according to the AJCC staging system, 8th edition. 3. Inflammatory breast cancer or breast rupture. 4. There are clinical symptoms or diseases of the heart that are not well controlled 5. Hypertension that is not well controlled by antihypertensive medication: systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg has a history of hypertensive crisis or hypertensive encephalopathy. 6. NCI-CTCAE v5.0 grade ≥2 bleeding events occurred within 4 weeks before the first medication, including but not limited to hemoptysis (single episode of hemoptysis volume ≥ 2mL), vaginal bleeding, gastrointestinal bleeding, etc. 7. Excessive arterial/venous thrombosis events occurred within 6 months before the first medication, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc. Patients with lower extremity intermuscular venous thrombosis who were evaluated as not requiring anticoagulant therapy, and those whose mural thrombus caused by catheterization had disappeared and did not require drug therapy were considered for enrollment. 8. Inability to swallow tablets normally or abnormal gastrointestinal function, which may affect drug absorption as judged by the researcher; 9. Receipt of a strong inhibitor of CYP3A4, CYP2D6, P-gp, or BCRP from the date of first dose \<5 times of drug half-lives or 14 days; The interval between receiving treatment with the above enzyme strong inducers and the first dose \< 28 days. 10. Evidence of any disease as judged by the investigator (e.g., severe or uncontrolled systemic disease, including severe systemic infection, uncontrolled hypertension, renal transplantation and active bleeding disease, coagulation disorders, platelet dysfunction, severe chronic gastrointestinal disease, or patients with other serious medical conditions); 11. Have undergone major surgery other than invasive diagnostic procedures, peripherally inserted central catheter (PICC) procedures, or pathological biopsy within 28 days prior to the first dose, or are expected to undergo major surgery during the study period; 12. Unhealed wounds, ulcers, or fractures; 13. Active hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] positive and HBV-DNA ≥500IU/ml); 14. Hepatitis C infection (defined as a positive test for hepatitis C virus antibody \[HCV-Ab\] and an HCV-RNA test higher than the lower limit of the assay); 15. Known history of human immunodeficiency virus (HIV) infection; 16. Known history of psychotropic substance abuse, alcohol or drug abuse; 17. Active psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, etc.) and depression being treated with antidepressants were not exclusion criteria. 18. Patients with known allergy or intolerance to the study drug or its excipents; 19. Patients of reproductive age who are pregnant or lactating, and who refuse to use appropriate contraception during the course of the trial; 20. Participated in other trial studies within 30 days before the first dose of the study drug, or not more than 5 half-lives since the last dose of the study drug; 21. Patients judged by the investigator to be ineligible for the study.
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 20000
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Biomarkers and clinicopathological information (up to 20-years)
  • Invasive disease-free survival (up to 20-years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2010-08
Completion: 2031-08
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lund University
Collaborators: South Sweden Breast Cancer Group, Mrs. Berta Kamprad Foundation, U-CAN
Principal Investigators:
  • Åke Borg, PhD (STUDY_DIRECTOR) - Lund University
  • Cecilia Hegardt, PhD (STUDY_CHAIR) - Lund University
  • Christer Larsson, PhD (PRINCIPAL_INVESTIGATOR) - Lund University
Contact Information
Study Contact:
Åke Borg, PhD
+46-46-2752552
ake.borg@med.lu.se
Lao Saal, MD, PhD
lao.saal@med.lu.se
Zakaria Einbeigi, PhD MD
+4603306161000
zakaria.einbeigi@oncology.gu.se
Södra Älvsborg Hospital
Interventions
N/A
Study Locations (10 sites)
Södra Älvsborg Hospital, Borås, Sweden
Hallands Hospital Halmstad, Halmstad, 30233 Sweden
Helsingborg Hospital, Helsingborg, 25187 Sweden
Kirurgiska kliniken, Jönköping, 55185 Sweden
Blekinge County Hospital, Karlskrona, 37185 Sweden
Central Hospital Kristianstad, Kristianstad, 29185 Sweden
Skåne University Hospital, Lund, 22185 Sweden
Skåne University Hospital, Malmö, 20502 Sweden
Uppsala University Hospital, Uppsala, 75185 Sweden
Central Hospital Växjö, Vaxjo, 35234 Sweden
Eligibility Criteria
Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent
Conditions Non-Small Cell Lung Cancer, Colorectal C...
Phase PHASE1
Enrollment 119
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 with or without chemotherapy and/or trastuzumab or cetuximab

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: FT836 — FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.
  • Drug: Cetuximab — Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion
  • Drug: Trastuzumab — Trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.

Primary Outcomes

  • Number of participants with dose limiting toxicities (DLTs) (From Day 1 through Day 29 of Cycle 1( each cycle is 56 days))
  • Severity of DLTs (From Day 1 through Day 29 of Cycle 1( each cycle is 56 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-11-04
Completion: 2030-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 119 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fate Therapeutics
Principal Investigators:
  • Lilly Wong, PhD (STUDY_DIRECTOR) - Fate Therapeutics, Inc.
Contact Information
Study Contact:
Fate Trial Disclosure
858-875-1800
FateTrialDisclosure@fatetherapeutics.com
Principle Investigator
University of Minnesota Masonic Cancer Center
Principle Investigator
Thomas Jefferson University, Sidney Kimmel Cancer Center
Interventions
  • Drug: FT836 — FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.
  • Drug: Cetuximab — Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion
  • Drug: Trastuzumab — Trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.
Study Locations (5 sites)
UC San Diego Moores Cancer Center, La Jolla, California 92093 United States
University of Southern California, Los Angeles, California 90033 United States
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota 55455 United States
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania 19107 United States
M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * For all regimens, disease that is not amenable to curative therapy and that has relapsed or progressed following at least one line of prior systemic therapy. * Evidence of adequate organ function as determined by all of the following: * Absolute neutrophil count (ANC) \>1000/µL without growth factor support within 7 days prior to start of first study intervention * Platelet count ≥75,000/µL without transfusion support within 14 days prior to start of first study intervention * Estimated creatinine clearance ≥50 mL/minute by Cockcroft-Gault method or other standard institutional method * Total bilirubin ≤1.5 × upper limit of normal (ULN); for participants with documented Gilbert syndrome, total bilirubin must be ≤3 ×ULN * Aspartate transaminase (AST) ≤3 × ULN or alanine transaminase (ALT) ≤3 × ULN; in participants with documented liver metastases, AST or ALT ≤5 × ULN * Alkaline phosphatase (ALP) ≤2.5 × ULN; in participants with documented liver or bone metastases, ALP ≤5 × ULN * Oxygen saturation \>90% on room air * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. * Presence of measurable disease by RECIST, v1.1 assessed within 28 days prior to start of first study intervention. * Presence of baseline safely accessible lesions of adequate size for on-treatment biopsies (exceptions for lesion size may be granted with medical monitor approval) and participant willingness to undergo protocol prescribed on-treatment biopsies. Exclusion Criteria: * Clinically significant cardiovascular disease including any of the following: uncontrolled/ unstable cardiac arrhythmias, myocardial infarction within 6 months prior to start of first study intervention, unstable angina or congestive heart failure of New York Heart Association (NYHA) Grade 2 or higher, or cardiac ejection fraction \<50%. * Receipt of any biological therapy, chemotherapy, investigational therapy, or radiation therapy within 2 weeks or five half-lives prior to start of first study intervention, whichever is shorter. * Known active central nervous system (CNS) involvement by malignancy. Participants with prior CNS involvement from their malignancy must have completed effective treatment of their CNS disease with no symptoms of disease in the absence of steroid treatment and at least stable findings on relevant CNS imaging and no evidence of leptomeningeal disease for at least 4 weeks prior to study enrollment. * Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions within 6 months prior to study enrollment. * Currently receiving or likely to require systemic immunosuppressive therapy (e.g., prednisone ≥5 mg daily) for any reason from start of first study intervention to Day 29 with the exception of corticosteroids as a premedication for chemotherapy side effects per institutional standard of care or as mandated by the protocol. * Any history of Grade ≥3 immune-related AE or Grade ≥2 eye toxicity attributed to prior cancer immunotherapy, other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase. * Grade ≥2 peripheral neuropathy limiting instrumental activities of daily living.
Conditions Breast Carcinoma, Colorectal Carcinoma, ...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Educational Intervention — Receive educational materials and resources
  • Other: Electronic Health Record Review — Ancillary studies
  • Procedure: Follow-Up — Receive follow-up contact
  • Other: Internet-Based Intervention — Use self-monitoring platform
  • Other: Interview — Ancillary studies
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Self-reported system usability (Up to 6 months)
  • Perceived usefulness (Up to 6 months)
  • Ease of use (Up to 6 months)
  • Attitudes toward use (Up to 6 months)
  • Intention to use and continuous use of the system over time (Up to 12 months)
  • Self-reported patient engagement (Up to 6 months)
  • System usage over time (Up to 12 months)
  • Patient activation levels (Up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-09
Completion: 2028-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan Rogel Cancer Center
Collaborators: Agency for Healthcare Research and Quality (AHRQ)
Principal Investigators:
  • Yun Jiang (PRINCIPAL_INVESTIGATOR) - University of Michigan Rogel Cancer Center
  • Yang Gong (PRINCIPAL_INVESTIGATOR) - UTHealth Houston McWilliam School of Biomedical Informatics
Contact Information
Study Contact:
Yun Jiang
734-763-3705
jiangyu@umich.edu
Yun Jiang
734-763-3705
jiangyu@umich.edu
University of Michigan Comprehensive Cancer Center
Yun Jiang
University of Michigan Comprehensive Cancer Center
Interventions
  • Other: Educational Intervention — Receive educational materials and resources
  • Other: Electronic Health Record Review — Ancillary studies
  • Procedure: Follow-Up — Receive follow-up contact
  • Other: Internet-Based Intervention — Use self-monitoring platform
  • Other: Interview — Ancillary studies
Study Locations (1 sites)
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Participants are adult patients (aged 18 years or older) * Diagnosed with lung, colorectal, breast, or prostate cancer * Are currently receiving active cancer treatments * Are self-managing one or more prescribed cancer medications * Participants must have access to technology devices (smartphone, tablet, computer) to track their experiences or concerns about medication safety events, or their family members can help them access technology devices to track the events or concerns * Speaks and reads English or has a support person (family member or friend) who can assist Exclusion Criteria: * Can't access technology or do not use technology * Do not have access to the internet * Do not speak or read English * Not permitted to participate by their health care providers